Growth Hormone Axis · Growth Hormone Axis peptide (research)
CJC-1295 with DAC
- Drug class
- Growth Hormone Axis peptide (research)
- Status
- Compounded (503A)
- Also known as
- cjc1295 dac, cjc with dac, cjc 1295 long acting
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What CJC-1295 with DAC is studied for
- Sustained GH release (research)
- Less frequent dosing (research)
- Body composition (research)
Mechanism of action
CJC-1295 with DAC is being studied in the growth hormone axis category. Long-acting GHRH analog with drug affinity complex for sustained GH support. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is CJC-1295 with DAC?
CJC-1295 with DAC is a growth hormone axis peptide. Long-acting GHRH analog with drug affinity complex for sustained GH support.
What is CJC-1295 with DAC studied for?
Published research has examined CJC-1295 with DAC for sustained gh release, less frequent dosing, body composition. Human clinical evidence varies by indication.
Is CJC-1295 with DAC FDA-approved?
No. CJC-1295 with DAC is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is CJC-1295 with DAC used in research?
Protocols vary by study. CJC-1295 with DAC is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for CJC-1295 with DAC is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.